IP Library › Granted Patent US 8,617,550
Granted Patent B2
US 8,617,550 · App. 10/596,429 · Granted Dec 31, 2013

Treatment of vasculitis with IL-6 antagonist

Inventors: Norihiro Nishimoto (Minoh, JP); Tadamitsu Kishimoto (Tondabayashi, JP); Hideko Nakahara (Osaka, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,617,550
App. No.
10/596,429
Granted
Dec 31, 2013
Kind
B2
Abstract

To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims (11)

1. A method of treating vasculitis comprising administering an antibody against interleukin-6 (IL-6) receptor to a subject in need thereof.

2. The method according to claim 1 wherein said vasculitis is polyarteritis nodosa.

3. The method according to claim 1 wherein said vasculitis is the aortitis syndrome.

4. The method according to claim 1 wherein said antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

5. The method according to claim 1 wherein said antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

6. The method according to claim 5 wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody.

7. The method according to claim 1 wherein said antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

8. The method according to claim 7 wherein said monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

9. The method according to claim 1 wherein said antibody against IL-6 receptor is a recombinant antibody.

10. The method according to claim 1 wherein said antibody against IL-6 receptor is a chimeric antibody, humanized antibody, or a human antibody against IL-6 receptor.

11. The method according to claim 10 wherein said humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2006
From: NISHIMOTO, NORIHIRO; KISHIMOTO, TADAMITSU; NAKAHARA, HIDEKO
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 018179/0904 →
Priority Claims (1)
JP 2003-423517 · Dec 19, 2003 · national
Continuity (1)
Related Publication 20070098714A1 · May 3, 2007